Cofactor-Mediated DNA Binding by the NF-kappaB Dimers
NF-kappaB 二聚体辅助因子介导的 DNA 结合
基本信息
- 批准号:9887959
- 负责人:
- 金额:$ 31.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary
The NF- κB dimers bind to specific DNA response elements known as the κB DNA sites located in the
promoters and enhancers of thousands of genes, and regulate their expression. Although the roughly 10 bp
long κB sequences follow a consensus, hundreds of specific sequences can fit the consensus. Sequence
variations can result in differences in NF-κB-DNA binding affinity, kinetics and conformations leading to
changes in transcriptional output. Indeed, other and we reported that as few as a single bp change can
have severe effect in gene regulation by the NF-κB dimers. Affinities of the NF-κB:DNA complexes derived
from in vitro experiments do not always correlate with in vivo binding and gene regulation. These
observations suggest that there are modulators present in the cell and without their inclusion in in vitro
experiments in vivo and in vitro results will not reconcile. On the other hand, without proper in vitro
experimental set up, proper investigation of regulatory mechanisms in vivo is difficult to accomplish.
Cellular experiments performed over the past 10 years established the presence of several of such
modulators, but their mechanisms of action could not be properly explained without thorough biochemical
and biophysical experiments. We term these modulators cofactors. These cofactors alter the DNA binding
affinity of NF-κB p50:RelA heterodimer and RelA homodimers in a κB sequence-specific manner. The
focus of this proposal is to use new experiments to propose a unifying principle of how the cofactors
regulate NF-κB activity.
We propose that when the affinity between an NF-κB:κB DNA complex is weak, a cofactor can act
positively enhancing the affinity of NF-κB:DNA complexes by directly contacting NF-κB without contacting
DNA allowing gene expression to occur. Alternatively, a cofactor can act negatively by removing NF-κB off
the DNA (or reduce affinity). Several positive cofactors and few negative cofactors are known. We will
investigate the mode of actions of a few of these cofactors in vitro. Specifically, we will identify the site of
interaction of both positive and negative cofactors on RelA and how they use allosteric mechanism to alter
DNA binding by RelA. Since no cofactor specific to p50 is known, we also plan to identify cofactors specific
to the p50 subunit and investigate if and how these new cofactors act together with RelA-specific cofactors.
We will generate mutants of RelA defective in cofactor binding and test how gene expression profile and
DNA binding in cells alters in response to specific stimulus.
项目摘要
NF-κB二聚体与特定的DNA响应元件结合,称为位于该位置的κBDNA位点
基因的启动子和增强子,并调节其表达。尽管大约10 bp
长κB序列遵循共识,数百个特定序列可以符合共识。顺序
变化会导致NF-κB-DNA结合亲和力,动力学和构象的差异,导致
转录输出的变化。确实,其他,我们报告说,只有一个BP更改可以
NF-κB二聚体对基因调节具有严重作用。 NF-κB的亲和力:衍生的DNA复合物
在体外实验并不总是与体内结合和基因调节相关。这些
观察结果表明,细胞中存在调节剂,并且不包含在体外
体内和体外结果的实验不会和解。另一方面,没有适当的体外
实验设置,在体内对监管机制的适当投资很难完成。
在过去的10年中进行的细胞实验确定了其中几个此类的存在
调节器,但是如果没有优先级的生化,无法正确解释其作用机制
和生物物理实验。我们称这些调节器辅助因子。这些辅助因子改变了DNA结合
NF-κBp50的亲和力:以κB序列特异性方式的Rela异二聚体和RELA同型二聚体。这
该提案的重点是使用新实验提出一个统一原则,以说明如何辅助因子
调节NF-κB活性。
我们建议,当NF-κB:κBDNA复合物之间的亲和力很弱时,辅助因子可以作用
通过直接接触NF-κB而无需接触,从而积极增强NF-κB:DNA复合物的亲和力
DNA允许发生基因表达。另外,辅助因子可以通过删除NF-κB来负面作用
DNA(或减少亲和力)。已知几个阳性辅因子和很少的负辅因子。我们将
在体外研究其中一些辅助因子的作用方式。具体来说,我们将确定
阳性和负辅因子在Rela上的相互作用以及它们如何使用变构机制改变
Rela的DNA结合。由于没有p50特定的辅助因子,因此我们还计划识别特定的辅助因子
到P50亚基,并研究这些新辅助因子是否以及如何与Rela特异性辅助因子一起起作用。
我们将在辅因子结合中产生Rela有缺陷的突变体,并测试基因表达谱和如何
细胞中的DNA结合对特定刺激的响应改变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
GOURISANKAR GHOSH的其他基金
Chromogranin A is an aging risk factor
嗜铬粒蛋白 A 是衰老的危险因素
- 批准号:1066726510667265
- 财政年份:2023
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Suppressing Inflammation by Blocking IKK Oligomer
通过阻断 IKK 寡聚物抑制炎症
- 批准号:1044609810446098
- 财政年份:2022
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Suppressing Inflammation by Blocking IKK Oligomer
通过阻断 IKK 寡聚物抑制炎症
- 批准号:1057321810573218
- 财政年份:2022
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Investigation of Gene Regulation by NF-kappaB Transcription factors
NF-kappaB 转录因子基因调控的研究
- 批准号:82601998260199
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Investigation of gene regulation by NF-kappaB transcription factors
NF-κB转录因子基因调控的研究
- 批准号:90218689021868
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
ASF/SF2: Phosphorylation and RNA Binding
ASF/SF2:磷酸化和 RNA 结合
- 批准号:81307858130785
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
IKK:Biophysical basis of dynamic regulation
IKK:动态调节的生物物理基础
- 批准号:80726338072633
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
IKK:Biophysical basis of dynamic regulation
IKK:动态调节的生物物理基础
- 批准号:84634068463406
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Investigation of gene regulation by NF-kappaB transcription factors
NF-κB转录因子基因调控的研究
- 批准号:89040298904029
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
ASF/SF2: Phosphorylation and RNA Binding
ASF/SF2:磷酸化和 RNA 结合
- 批准号:79077687907768
- 财政年份:2009
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
相似国自然基金
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于深度学习预测小分子与人类突变激酶结合亲和力的研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
反复非平衡结合联合迭代筛选发掘混合物中痕量高亲和力配体的方法及其应用
- 批准号:82273900
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
全新从头快速设计靶向COVID-19病毒及其突变株S蛋白超高亲和力阻断结合蛋白研究
- 批准号:
- 批准年份:2022
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:1075255510752555
- 财政年份:2024
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
- 批准号:1067834110678341
- 财政年份:2023
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Natural products inhibitors targeting homology-directed DNA repair for cancer therapy
针对癌症治疗的同源定向 DNA 修复的天然产物抑制剂
- 批准号:1065104810651048
- 财政年份:2023
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Harnessing iron acquisition to hinder enterobacterial pathogenesis
利用铁的获取来阻碍肠细菌的发病机制
- 批准号:1065143210651432
- 财政年份:2023
- 资助金额:$ 31.44万$ 31.44万
- 项目类别:
Alpha-Synuclein-Specific T cells in Parkinson's Disease Pathogenesis
帕金森病发病机制中的α-突触核蛋白特异性 T 细胞
- 批准号:1075217210752172
- 财政年份:2023
- 资助金额:$ 31.44万$ 31.44万
- 项目类别: